UNSPSC 51351602: Aglepristone

This classification denotes an anti-progestin, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0UT4JLE1CM. European Medicines Agency schedules Aglepristone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05285MIG. Aglepristone generally arises in the molecular formula C29H37NO2.

UNSPSC 51351602 Aglepristone is a Commodity code encompassing a synthetic progestin pharmaceutical product. State and local governments procure aglepristone and related generic pharmaceuticals primarily through cooperative purchasing vehicles that aggregate demand across multiple jurisdictions and facility types, including state health departments, local public health agencies, and municipal healthcare systems. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary issuing body using this code in recent procurement activity. Solicitations under this code require manufacturers and authorized distributors to supply products meeting cGMP and Drug Supply Chain Security Act (DSCSA) compliance standards, with detailed product specifications including National Drug Codes (NDCs), SKUs, UPCs, dosage forms, strength, and packaging configurations. Vendors must maintain contractual relationships with authorized pharmaceutical wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health, and Morris & Dickson Co., LLC), hold comprehensive insurance coverage including $5,000,000 in commercial general liability and $2,000,000 in network security and privacy liability, and accept performance penalties ranging from $200 to $1,500 per violation for late reporting, missed onboarding, or improper class-of-trade denials.

MMCAP's January 2026 RFP for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026, spans Minnesota and Oregon participation. Evaluation emphasizes price competitiveness (75 percent weight) and administrative compliance, with awarded vendors taking effect July 1, 2026, under a two-year initial contract term with optional extensions at MMCAP's sole discretion. Vendors must demonstrate pricing flexibility through flat price, net price formats (NF30, NF60, NF90), or WAC-minus structures, and all products require minimum six-month shelf life with expiration dates at least one year from manufacture. The RFP does not identify explicit set-aside designations or restrictions to particular business classifications; however, all submissions must use the ePro procurement system and comply with FDA requirements. No specific budget or award value is disclosed in the solicitation.